These TCRs, when engineered into CD8+ and CD4+ T-cells, restored cytotoxic activity against EBV-infected cells and may serve as a foundation for adoptive T-cell therapies in EBV-driven lymphomas, including cHL. The gene discussed is CD8A; the disease is classic Hodgkin lymphoma.